(Q80177579)

English

Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen

scientific article published on 01 January 2006

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16937274%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16937274%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

author name string

Hideaki Kishimoto

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16937274%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Masao Fukunaga

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16937274%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Kazuhiro Kushida

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16937274%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Masataka Shiraki

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16937274%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Akira Itabashi

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16937274%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Hajime Nawata

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16937274%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Toshitaka Nakamura

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16937274%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Hiroaki Ohta

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16937274%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Kunio Takaoka

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16937274%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Yasuo Ohashi

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16937274%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Risedronate Phase III Research Group

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16937274%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

publication date

1 January 2006

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16937274%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Journal of Bone and Mineral Metabolism

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16937274%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

24

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16937274%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16937274%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

405-413

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16937274%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Weekly administration of alendronate: rationale and plan for clinical assessment

1 reference

https://pubmed.ncbi.nlm.nih.gov/16937274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women

1 reference

https://pubmed.ncbi.nlm.nih.gov/16937274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/16937274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16937274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/16937274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/16937274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diagnostic criteria for primary osteoporosis: year 2000 revision

1 reference

https://pubmed.ncbi.nlm.nih.gov/16937274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bisphosphonates: a review of their pharmacokinetic properties

1 reference

https://pubmed.ncbi.nlm.nih.gov/16937274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/16937274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/16937274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16937274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/16937274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers

1 reference

https://pubmed.ncbi.nlm.nih.gov/16937274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group)

1 reference

https://pubmed.ncbi.nlm.nih.gov/16937274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/16937274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Seven years of treatment with risedronate in women with postmenopausal osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16937274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate

1 reference

https://pubmed.ncbi.nlm.nih.gov/16937274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical trial of risedronate in Japanese volunteers: single and multiple oral dose studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/16937274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Total administered dose of ibandronate determines its effects on bone mass and architecture in ovariectomized aged rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/16937274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16937274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16937274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/16937274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience

1 reference

https://pubmed.ncbi.nlm.nih.gov/16937274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/16937274

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00774-006-0706-Z

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16937274%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16937274%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q80177579&oldid=2220833218"